Literature DB >> 16427213

Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology.

Isabelle Flandin1, Olivier Hartmann, Jean Michon, Ross Pinkerton, Carole Coze, Jean Louis Stephan, Bernard Fourquet, Dominique Valteau-Couanet, Christophe Bergeron, Thierry Philip, Christian Carrie.   

Abstract

PURPOSE: To determine the contribution of total body irradiation (TBI) to late sequelae in children treated with high-dose chemotherapy and autologous bone marrow transplantation for Stage IV neuroblastoma. PATIENTS AND METHODS: We compared two populations that were similar with regard to age, stage, pre-autologous bone marrow transplantation chemotherapy (CT) regimen, period of treatment, and follow-up (12 years). The TBI group (n = 32) received TBI as part of the megatherapy procedure (1982-1993), whereas the CT group (n = 30) received conditioning without TBI (1985-1992). Analysis 12 years later focused on growth, weight and corpulence (body mass index) delay; hormonal deficiencies; liver, kidney, heart, ear, eye, and dental sequelae; school performance; and the incidence of secondary tumors.
RESULTS: Impact of TBI was most marked in relation to growth and weight delay, although the mean delay was not severe, probably because of treatment with growth hormones. Other consequences of TBI were thyroid insufficiency, cataracts, and a high incidence of secondary tumors. Hearing loss and dental agenesis were more prominent in the group treated with CT alone. No differences were observed in school performance.
CONCLUSION: The most frequent side effects of TBI were cataracts, thyroid insufficiency, and growth delay, but more worrying is the risk of secondary tumors. Because of the young mean age of patients and the toxicity of TBI regimens without any survival advantage, regimens without TBI are preferable in the management of Stage IV neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16427213     DOI: 10.1016/j.ijrobp.2005.10.020

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  26 in total

1.  Osteochondroma in long-term survivors of high-risk neuroblastoma.

Authors:  Brian H Kushner; Stephen S Roberts; Danielle N Friedman; Deborah Kuk; Irina Ostrovnaya; Shakeel Modak; Kim Kramer; Ellen M Basu; Nai-Kong V Cheung
Journal:  Cancer       Date:  2015-02-27       Impact factor: 6.860

2.  Second cancer after total-body irradiation (TBI) in childhood.

Authors:  Pascal Pommier; Marie Pierre Sunyach; Caroline Pasteuris; Didier Frappaz; Christian Carrie
Journal:  Strahlenther Onkol       Date:  2009-08       Impact factor: 3.621

3.  Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma.

Authors:  Sara M Federico; Heather B Allewelt; Sheri L Spunt; Melissa M Hudson; Jianrong Wu; Catherine A Billups; Jesse Jenkins; Victor M Santana; Wayne L Furman; Lisa M McGregor
Journal:  J Pediatr Hematol Oncol       Date:  2015-01       Impact factor: 1.289

4.  Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma: the Korean Society of Pediatric Hematology-Oncology experience over 6 years (2000-2005).

Authors:  Ki Woong Sung; Hyo Seop Ahn; Bin Cho; Yong-Mook Choi; Nack Gyun Chung; Tai Ju Hwang; Ho Joon Im; Dae Chul Jeong; Hyoung Jin Kang; Hong Hoe Koo; Hoon Kook; Hack Ki Kim; Chuhl Joo Lyu; Jong Jin Seo; Hee Young Shin; Keon Hee Yoo; Sung Chul Won; Kun Soo Lee
Journal:  J Korean Med Sci       Date:  2010-04-21       Impact factor: 2.153

5.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

Authors:  Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

6.  Hepatotoxicity after liver irradiation in children and adolescents : results from the RiSK.

Authors:  Pascal Rösler; Hans Christiansen; Rolf-Dieter Kortmann; Carmen Martini; Christiane Matuschek; Frank Meyer; Christian Rübe; Thorsten Langer; Raphael Koch; Hans Theodor Eich; Normann Willich; Diana Steinmann
Journal:  Strahlenther Onkol       Date:  2014-12-09       Impact factor: 3.621

7.  Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.

Authors:  Kelly E Huibregtse; Kieuhoa T Vo; Steven G DuBois; Stephanie Fetzko; John Neuhaus; Vandana Batra; John M Maris; Brian Weiss; Araz Marachelian; Greg A Yanik; Katherine K Matthay
Journal:  Eur J Cancer       Date:  2016-08-27       Impact factor: 9.162

8.  Risk of cataract extraction among adult retinoblastoma survivors.

Authors:  Gabriel Chodick; Ruth A Kleinerman; Marilyn Stovall; David H Abramson; Johanna M Seddon; Susan A Smith; Margaret A Tucker
Journal:  Arch Ophthalmol       Date:  2009-11

9.  The role of chest computed tomography (CT) as a surveillance tool in children with high-risk neuroblastoma.

Authors:  Sara M Federico; Samuel L Brady; Alberto Pappo; Jianrong Wu; Shenghua Mao; Valerie J McPherson; Alison Young; Wayne L Furman; Robert Kaufman; Sue Kaste
Journal:  Pediatr Blood Cancer       Date:  2015-01-13       Impact factor: 3.167

10.  High-dose chemotherapy and autologous stem cell rescue in patients with high-risk stage 3 neuroblastoma: 10-year experience at a single center.

Authors:  Jung Min Suh; Keon Hee Yoo; Ki Woong Sung; Ju Youn Kim; Eun Joo Cho; Hong Hoe Koo; Suk Koo Lee; Jhingook Kim; Do Hoon Lim; Yeon Lim Suh; Dae Won Kim
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.